Triple-drug GVHD prophylaxis after HLA-matched unrelated donor non-myeloablative allogenic hematopoietic stem cell transplantation.

[1]  Ting Chen,et al.  The Addition of Sirolimus to GVHD Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation: A Meta-Analysis of Efficacy and Safety , 2021, Frontiers in Oncology.

[2]  J. Pérez-Simón,et al.  Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions. , 2020, Blood reviews.

[3]  N. Kröger,et al.  Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. , 2020, The Lancet. Haematology.

[4]  J. Perfect,et al.  Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  A. Nagler,et al.  Summary of Scientific and Statistical Methods, Study Endpoints and Definitions for Observational and Registry-Based Studies in Hematopoietic Cell Transplantation , 2019, Clinical hematology international.

[6]  S. Montoto,et al.  Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors , 2019, Bone Marrow Transplantation.

[7]  M. Maris,et al.  Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. , 2019, The Lancet. Haematology.

[8]  R. Leavitt,et al.  A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M. Hickson,et al.  Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies. , 2019, Clinical nutrition.

[10]  M. Mohty,et al.  The EBMT: History, Present, and Future , 2018, The EBMT Handbook.

[11]  Kamlesh Khunti,et al.  Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician , 2018, Advances in Therapy.

[12]  E. Holler,et al.  EBMT—NIH—CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment , 2018, Bone Marrow Transplantation.

[13]  B. Blazar,et al.  Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. , 2017, The New England journal of medicine.

[14]  Michael Boeckh,et al.  Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic‐Cell Transplantation , 2017, The New England journal of medicine.

[15]  B. Blazar,et al.  Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. , 2017, The New England journal of medicine.

[16]  H. Deeg,et al.  Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. , 2014, Blood.

[17]  Borsika A. Rabin,et al.  Uptake and use of recommendations for the diagnosis, severity scoring and management of chronic graft-versus-host disease: An international survey of the EBMT-NCI Chronic GVHD Task Force , 2013, Bone Marrow Transplantation.

[18]  H. Deeg,et al.  Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  H. Deeg,et al.  A disease risk index for patients undergoing allogeneic stem cell transplantation. , 2012, Blood.

[20]  M. Horowitz,et al.  Risk factors for acute GVHD and survival after hematopoietic cell transplantation. , 2012, Blood.

[21]  R. Storb,et al.  Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. , 2011, Blood.

[22]  A. Gratwohl,et al.  Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  G. Kemmler,et al.  Impact of GvHD on quality of life in long-term survivors of haematopoietic transplantation , 2010, Bone Marrow Transplantation.

[24]  P. Reddy,et al.  GVHD pathophysiology: is acute different from chronic? , 2008, Best practice & research. Clinical haematology.

[25]  M. Sorror,et al.  Hematopoietic cell transplantation‐comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation , 2008, Cancer.

[26]  D. Blaise,et al.  HLA Association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[27]  I. Bassett,et al.  Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. , 2007, Blood.

[28]  Edward A Copelan,et al.  Hematopoietic stem-cell transplantation. , 2006, The New England journal of medicine.

[29]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  A. Thomson,et al.  Rapamycin inhibits IL-4--induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. , 2003, Blood.

[31]  P. Allavena,et al.  Rapamycin impairs antigen uptake of human dendritic cells1 , 2003, Transplantation.

[32]  J Wagner,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[33]  M. Pepe,et al.  Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. , 1994, Blood.

[34]  D. Porter,et al.  International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[35]  R. Negrin,et al.  Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. , 2008, Blood.

[36]  J. Moake,et al.  Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. , 2007, Haematologica.